ARCHIVES

FEBT, For Pain Control, Shows Positive Results In Phase III

This article is from The Cancer Letter archive.

Vol. 29 No. 5 | May 26, 2006

Download PDF Visit The Full Archive

Related Articles

Clinical Practice Guidelines Don’t Meet IOM Standards

June 26, 2013

Rituximab Prolonged Survival Of CLL In Phase III Study

September 24, 2010

Natcher Subcommittee Kills Recision, Save NCI $17 Million

May 2, 1980

NCAB Votes Down Effort to Delay CCOP RFA, Directs Subcommittee To Look Again A Program Components

February 12, 1982

New Treatment Approaches Valuable For Cancer Pain, Quality Of Life

September 27, 2002

Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia

September 27, 2013